Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.70 |
| ▸ | FPR1 | P21462 | 2/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | FPR2 | P25090 | 3/20 | 0.58 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.58 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.58 |
| ▸ | ENPP1 | P22413 | 5/20 | 0.56 |
| ▸ | MPO | P05164 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16208396 | 0.89 | PTPN1 (0.59) | MAPTFPR1ALDH1A1MEN1LMNA | |
| SCHEMBL16208433 | 0.88 | MAPT (0.56) | MAPTFPR1ALDH1A1MEN1LMNA | |
| SCHEMBL16208350 | 0.87 | MAPT (0.67) | MAPTFPR1ALDH1A1MEN1LMNA | |
| SCHEMBL17538653 | 0.87 | MAPT (0.56) | MAPTFPR1ALDH1A1MEN1LMNA | |
| SCHEMBL20379521 | 0.86 | MAPT (0.85) | MAPTFPR1ALDH1A1MEN1LMNA | |
| SCHEMBL17531756 | 0.84 | MPO (0.73) | MAPTFPR1ALDH1A1MEN1LMNA | |
| SCHEMBL17538661 | 0.84 | ENPP1 (0.70) | MAPTFPR1ALDH1A1MEN1LMNA | |
| SCHEMBL16208361 | 0.83 | MAPT (0.68) | MAPTFPR1ALDH1A1MEN1LMNA | |
| SCHEMBL16208394 | 0.82 | ALDH1A1 (0.59) | MAPTFPR1ALDH1A1MEN1LMNA | |
| SCHEMBL16208415 | 0.81 | MAPT (0.57) | MAPTFPR1MEN1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9643933-B2 | Compounds useful as antibiotic tolerance inhibitors | THE GENERAL HOSPITAL CORPORATION (US) | 2017-05-09 | — | — | US | disclosed |
| US-20160052890-A1 | COMPOUNDS USEFUL AS ANTIBIOTIC TOLERANCE INHIBITORS | THE GENERAL HOSPITAL CORPORATION (US) | 2016-02-25 | — | — | US | disclosed |
| WO-2014176258-A1 | COMPOUNDS USEFUL AS ANTIBIOTIC TOLERANCE INHIBITORS | THE GENERAL HOSPITAL CORPORATION (US) | 2014-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160052890-A1 | COMPOUNDS USEFUL AS ANTIBIOTIC TOLERANCE INHIBITORS | CFTR, SLC11A2, MRPS18A | MAPT 4629/4885FPR1 1673/4885ALDH1A1 2988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.